Mechanisms of cordycepin in the treatment of pulmonary arterial hypertension in rats based on metabonomics and transcriptomics

Jiangpeng Lin,Riken Chen,Huizhao Liao,Yuzhuo Zhang,Zhenzhen Zheng,Cheng Hong
DOI: https://doi.org/10.1038/s41598-024-62163-3
IF: 4.6
2024-05-31
Scientific Reports
Abstract:Pulmonary arterial hypertension (PAH) is a fatal disease featured by high morbidity and mortality. Although Cordycepin is known for its anti-inflammatory, antioxidant and immune-enhancing effects, its role in PAH treatment and the underlying mechanisms remain unclear. The therapeutic effects of Cordycepin on rats with PAH were investigated using a monocrotaline (MCT)-induced rat model. The metabolic effects of Cordycepin were assessed based on the plasma metabolome. The potential mechanisms of Cordycepin in PAH treatment were investigated through transcriptome sequencing and validated in pulmonary artery smooth muscle cells (PASMC). Evaluations included hematoxylin and eosin staining for pulmonary vascular remodeling, CCK-8 assay, EDU, and TUNEL kits for cell viability, proliferation, and apoptosis, respectively, and western blot for protein expression. Cordycepin significantly reduced right ventricular systolic pressure (RVSP) and right ventricular hypertrophy index (RVHI) in PAH rats, and mitigated pulmonary vascular remodeling. Plasma metabolomics showed that Cordycepin could reverse the metabolic disorders in the lungs of MCT-induced PAH rats, particularly impacting linoleic acid and alpha-linolenic acid metabolism pathways. Transcriptomics revealed that the P53 pathway might be the primary pathway involved, and western blot results showed that Cordycepin significantly increased P53 and P21 protein levels in lung tissues. Integrated analysis of transcriptomics and metabolomics suggested that these pathways were mainly enriched in linoleic acid metabolism and alpha-linolenic acid metabolism pathway. In vitro experiments demonstrated that Cordycepin significantly inhibited the PDGFBB (PD)-induced abnormal proliferation and migration of PASMC and promoted PD-induced apoptosis. Meanwhile, Cordycepin enhanced the expression levels of P53 and P21 proteins in PD-insulted PASMC. However, inhibitors of P53 and P21 eliminated these effects of Cordycepin. Cordycepin may activate the P53–P21 pathway to inhibit abnormal proliferation and migration of PASMC and promote apoptosis, offering a potential approach for PAH treatment.
multidisciplinary sciences
What problem does this paper attempt to address?
The paper aims to explore the mechanism of action of Cordycepin in the treatment of pulmonary arterial hypertension (PAH). Specifically, the study addresses the issue through the following points: 1. **Experimental Model**: The study uses a monocrotaline (MCT)-induced rat model to simulate pulmonary arterial hypertension and evaluate the therapeutic effects of Cordycepin. 2. **Metabolomics Analysis**: Through plasma metabolomics analysis, the study found that Cordycepin can reverse the metabolic disorders in MCT-induced PAH rats, particularly affecting the linoleic acid and α-linolenic acid metabolic pathways. 3. **Transcriptomics Analysis**: Through transcriptome sequencing, the study revealed that the P53 pathway might be one of the main mechanisms by which Cordycepin treats PAH. Western blot results showed that Cordycepin significantly increased the expression levels of P53 and P21 proteins in lung tissue. 4. **Cellular Experiment Validation**: In vitro experiments showed that Cordycepin significantly inhibited the abnormal proliferation and migration of pulmonary arterial smooth muscle cells (PASMC) induced by platelet-derived growth factor (PDGFBB) and promoted apoptosis induced by PDGFBB. Additionally, inhibitors of P53 and P21 eliminated these effects of Cordycepin. In summary, the paper, through a comprehensive approach combining metabolomics and transcriptomics, reveals that Cordycepin may inhibit the abnormal proliferation and migration of PASMC and promote apoptosis by activating the P53-P21 pathway, thereby providing a potential new method for the treatment of PAH.